Bruce M. Wexler

Bruce M. Wexler is a senior patent litigator and a partner at Paul Hastings, where he co-chairs the firm's global intellectual property practice. His work centers on high-stakes disputes in the life sciences sector, with a particular emphasis on representing branded pharmaceutical and biotechnology companies in enforcing their patent rights. This focus is consistent with his role as lead counsel for the plaintiff Veloxis Pharmaceuticals AS in its litigation against Zydus Cadila.

Wexler's practice involves extensive trial and appellate work for major industry clients in "bet-the-company" cases, often related to the Hatch-Waxman Act. He has served as lead counsel for companies such as BioNTech, Merck, Eli Lilly, and Actelion in enforcement and defense matters involving blockbuster drug products. His notable successes include achieving a complete trial victory for Merck concerning its drug Emend® and representing BioNTech in litigation involving its COVID-19 vaccine. While the provided case list shows a plaintiff-side appearance, his firm biography notes that he handles both patent enforcement and defense matters.

In addition to his district court trial work, Wexler has experience before the Patent Trial and Appeal Board (PTAB), having successfully invalidated a patent on behalf of petitioner Eisai in a Post-Grant Review proceeding. His background includes a clerkship for the Honorable Chief Judge Glenn L. Archer, Jr. at the U.S. Court of Appeals for the Federal Circuit.

Wexler received his J.D. from New York University School of Law and a B.S. from Rensselaer Polytechnic Institute. He also serves as an adjunct professor at NYU School of Law, teaching a course on life sciences and patent law.